pembrolizumab - Robuta Search

https://adisinsight.springer.com/drugsafety/803181991?error=cookies_not_supported&code=c8646d1a-5113-432a-8ebe-eaabe202ed58 Pembrolizumab - AdisInsight A 51-year-old woman developed eosinophilic fasciitis following treatment with pembrolizumab. The woman received treatment with pembrolizumab, as a first-line pembrolizumab adisinsight https://publikationen.uni-tuebingen.de/xmlui/handle/10900/159657?show=full Perioperativer Einsatz von Pembrolizumab bei muskelinvasivem Blasenkarzinom einsatz von pembrolizumab bei blasenkarzinom https://adisinsight.springer.com/drugsafety/803924884?error=cookies_not_supported&code=66202f34-13eb-4047-a9c2-71ba44dcfd79 Carboplatin/Paclitaxel/Pembrolizumab - AdisInsight A 66-year-old man with stage IVB squamous cell carcinoma of the left upper lung and hepatic metastasis experienced lack of efficacy during treatment with carboplatin paclitaxel pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803910386?error=cookies_not_supported&code=a3c55992-d06e-40d3-bb4a-0b0a9c33628f Lenvatinib/Pembrolizumab - AdisInsight A cohort of 92 elderly patients with advanced recurrent endometrial cancer received combination therapy with lenvatinib and pembrolizumab. Lenvatinib was lenvatinib pembrolizumab adisinsight https://adisinsight.springer.com/trials/700319990?error=cookies_not_supported&code=6af18599-f2b7-4873-96f5-1febb7aea633 A Phase 1 Clinical Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory... The purpose of this study is to evaluate the objective response, safety, and tolerability of pembrolizumab in Japanese participants who have refractory primary https://boris-portal.unibe.ch/entities/publication/621a2804-e410-4bfb-840c-dd18a048d631 Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer... BACKGROUND HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast... pembrolizumab plus trastuzumab resistant advanced https://adisinsight.springer.com/trials/700252931?error=cookies_not_supported&code=df506d0a-e0f2-45d5-89eb-4a74b752ed06 A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer... This phase Ib/II trial is investigating the efficacy and safety of pembrolizumab combined with traditional chemotherapy drugs in patients with advanced https://adisinsight.springer.com/drugsafety/803743568?error=cookies_not_supported&code=bd084224-9b23-4401-8441-aa37c5447cb3 Pembrolizumab/carboplatin/etoposide - AdisInsight A 63-year-old woman developed pyogenic ventriculitis and autoimmune colitis during an off label treatment with pembrolizumab. Additionally, she developed pembrolizumab carboplatin etoposide adisinsight https://pubmed.ncbi.nlm.nih.gov/31175402/ Pembrolizumab as first-line treatment for metastatic uveal melanoma The efficacy of Pembrolizumab does not seem particularly different when compared to other agents for mUM, but responding patients had a remarkable disease... first line treatment for pembrolizumab metastatic melanoma https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02263508&r=1 Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma - NCI Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma pembrolizumab placebo melanoma nci https://pubmed.ncbi.nlm.nih.gov/38603953/ Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An... Pembrolizumab and epacadostat demonstrated an ORR of 21% in this small cohort of recurrent OCCC. The rapid rate of accrual highlights the enthusiasm and need... https://adisinsight.springer.com/drugsafety/803843517?error=cookies_not_supported&code=59497d2f-516e-46e1-9307-f0b82c237de8 Pembrolizumab - AdisInsight A 71-year-old woman developed Sjogren's syndrome during treatment with pembrolizumab for metastatic non-small cell lung cancer [route, dosage and duration of pembrolizumab adisinsight https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction... On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for... fda approves https://pmc.ncbi.nlm.nih.gov/articles/PMC10419154/ Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review - PMC Pembrolizumab has been shown to increase survival in patients with metastatic melanoma. Considering the numerous oncoming studies, we decided to conduct a... narrative review efficacy pembrolizumab advanced melanoma https://www.cancer.gov/news-events/cancer-currents-blog/2015/pembrolizumab-nsclc FDA Approves Pembrolizumab to Treat Non-Small Cell Lung Cancer - NCI The FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1. small cell lung cancer fda approves pembrolizumab treat https://pubmed.ncbi.nlm.nih.gov/35045221/ Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced... for advanced lenvatinib plus pembrolizumab endometrial https://pmc.ncbi.nlm.nih.gov/articles/PMC8076052/ The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa... Treatment of recurrent, unresectable granulosa cell tumor (GCT) of the ovary can be challenging. Given the rarity of the tumor, alternative therapies have been... https://experts.umn.edu/en/publications/histiocytic-sarcoma-treated-with-pembrolizumab-a-case-report-and-/ Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review -... histiocytic sarcoma case report treated pembrolizumab https://adisinsight.springer.com/drugsafety/803742463?error=cookies_not_supported&code=b6851689-1367-4b57-acc1-84f15c37e305 Atezolizumab/pembrolizumab - AdisInsight In a case series, involving 2 patients (a 64-year-old man and a 66-year-old woman), of whom 1 patient developed erythema, desquamation, erosion along with atezolizumab pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803469771?error=cookies_not_supported&code=17cf7dab-d8d5-49ee-9bc8-c8420ab1f9c0 Ipilimumab/nivolumab/pembrolizumab - AdisInsight A retrospective review of 64 patients, described 6 patients [ages and sexes not stated], who developed colitis, hepatitis, diarrhoea, uveitis, Bell's paly or ipilimumab nivolumab pembrolizumab adisinsight https://pubmed.ncbi.nlm.nih.gov/28515943/?dopt=Abstract Evaluation of dosing strategy for pembrolizumab for oncology indications Doses of 200 mg and 2 mg/kg provide similar exposure distributions with no advantage to either dosing approach with respect to controlling PK variability.... evaluation dosing strategy pembrolizumab oncology https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-05152&r=1 Brentuximab Vedotin in Combination with Pembrolizumab for the Treatment of Patients with CD30... Brentuximab Vedotin in Combination with Pembrolizumab for the Treatment of Patients with CD30 Positive T-cell Non-Hodgkin Lymphoma brentuximab vedotin https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-06279&r=1 Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects... Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-04695&loc=0&q=NRG-GY037&rl=1 Induction Pembrolizumab and Chemotherapy followed by Pembrolizumab before Chemoradiation and... Induction Pembrolizumab and Chemotherapy followed by Pembrolizumab before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation with... followed by induction pembrolizumab chemotherapy https://adisinsight.springer.com/drugsafety/803661658?error=cookies_not_supported&code=1a20021a-f9be-4130-9e9b-6eae83fbab53 Pembrolizumab - AdisInsight An 80-year-old woman developed hypothyroidism during treatment with pembrolizumab for conjunctival malignant melanoma [duration of treatment to reaction onset pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803926247?error=cookies_not_supported&code=6089d91f-94c8-4311-9eac-a06ac2b20819 Pembrolizumab - AdisInsight Eighty-two patients with triple-negative breast cancer received neoadjuvant chemotherapy with pembrolizumab and subsequently developed immune-related adverse pembrolizumab adisinsight https://pubmed.ncbi.nlm.nih.gov/32451495/ BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic... Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative... https://adisinsight.springer.com/trials/700372498?error=cookies_not_supported&code=1a9c70f9-c999-4dd5-87ca-eb79d1b335b8 A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab... This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with locally advanced or metastatic https://pubmed.ncbi.nlm.nih.gov/31961766/ Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma,... Lenvatinib plus pembrolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with selected solid tumor types. https://itila.blogspot.com/2016/04/wonder-drug-pembrolizumab-nearly-killed.html?showComment=1461063854750 Everything is Connected: Wonder-drug Pembrolizumab nearly killed me Chapter 23 - a downhill adventure As I said in Chapter 22, I have been feeling increasingly breathless. Once we got to Snowdonia, this t... everything is connected wonder drug pembrolizumab nearly https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection | FDA On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous... fda approves pembrolizumab alfa subcutaneous injection https://digitalcommons.wustl.edu/oa_4/6464/ "LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemt" by Jean-Pascal Machiels,... Patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) have limited treatment options and a dismal prognosis, especially when... https://experts.arizona.edu/en/publications/sustained-response-to-pembrolizumab-in-recurrent-perivascular-epi/ Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated... https://adisinsight.springer.com/drugsafety/803270617?error=cookies_not_supported&code=3777723d-0708-445e-8dd5-9b331cc7e7d8 Dacarbazine/pembrolizumab - AdisInsight A 42-year-old man developed bullous pemphigoid like drug eruption during therapy with pembrolizumab and fatigue with dryness of skin during therapy with dacarbazine pembrolizumab adisinsight https://pubmed.ncbi.nlm.nih.gov/31815178/ Pembrolizumab microgravity crystallization experimentation Crystallization processes have been widely used in the pharmaceutical industry for the manufacture, storage, and delivery of small-molecule and small protein... pembrolizumab microgravity crystallization experimentation https://adisinsight.springer.com/drugsafety/803820990?error=cookies_not_supported&code=a09a8def-021d-47cf-87b7-9e44398c1b1e Catequentinib/pembrolizumab - AdisInsight A 54-year-old woman developed hepatitis, liver cirrhosis and hypothyroidism during treatment with pembrolizumab for pulmonary lymphoepithelioma-like carcinoma pembrolizumab adisinsight https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer | FDA On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and... fda approves treatment for https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02358031 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous... A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) https://pmc.ncbi.nlm.nih.gov/articles/PMC12747779/ Fatal Tumor Lysis Syndrome Induced by Pembrolizumab in Advanced Renal Pelvis Cancer - PMC Tumor lysis syndrome (TLS) arises from the rapid breakdown of tumor cells during oncological treatment. Although TLS is rarely observed in solid tumors, few... tumor lysis syndrome https://adisinsight.springer.com/trials/700265955?error=cookies_not_supported&code=10f0e8b7-143c-4e03-8d39-da7f0a6868cc A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer -... This study is investigating immunotherapy with pembrolizumab in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced https://adisinsight.springer.com/drugsafety/803929032?error=cookies_not_supported&code=f70d8d9d-8372-4406-bd5f-46f3eea05bb5 Pembrolizumab - AdisInsight A 72-year-old man with non small cell lung cancer of the right middle lobe and pericardial metastasis, treated with the immune checkpoint inhibitor pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803485242?error=cookies_not_supported&code=a8dc0c1e-6413-4880-b8de-878b33d71f36 Pembrolizumab - AdisInsight Details of this case report have previously been published and processed for Adis PV [see Reactions 1767 p257; [1] ]. In this article it was reported that the pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803927245?error=cookies_not_supported&code=bd87135a-c60c-4e10-bfd1-7d5f3d0bf344 Pembrolizumab - AdisInsight A 76-year-old man with cutaneous melanoma experienced a rare isolated fourth cranial nerve palsy while receiving adjuvant pembrolizumab [dose and route not pembrolizumab adisinsight https://health.economictimes.indiatimes.com/tag/pembrolizumab Pembrolizumab - Latest pembrolizumab , Information & Updates - Health -ET HealthWorld ETHealthworld.com brings latest pembrolizumab news, views and updates from all top sources for the Indian Health industry. latest information pembrolizumab updates health et https://pubmed.ncbi.nlm.nih.gov/33141975/ A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen... The combination of enobosarm and pembrolizumab was well tolerated, with a modest clinical benefit rate of 25% at 16 weeks in heavily pretreated AR+ TNBC... https://adisinsight.springer.com/drugsafety/803929578?error=cookies_not_supported&code=1d053651-fc07-43c9-aaa6-647d80bdc0df Lenvatinib/Pembrolizumab - AdisInsight A 64-year-old man with metastatic renal cell carcinoma experienced acute kidney injury and nephrotic syndrome, with kidney biopsy demonstrating diffuse lenvatinib pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803899453?error=cookies_not_supported&code=26b50769-42cf-4c58-9520-29bcdf3ac02e Ipilimumab/nivolumab/pembrolizumab - AdisInsight In a study of 60 patients conducted between January 2008 and January 2018, 5 patients (3 women and 2 men) aged between 29 and 66 years were described, who ipilimumab nivolumab pembrolizumab adisinsight https://www.newswire.ca/news-releases/mercks-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of-pd-l1-563027051.html Merck's Pembrolizumab Significantly Improves Survival Compared to Chemotherapy in... /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside Canada and the United States, today announced results from the pivotal KEYNOTE-010 study, the first... compared to merck pembrolizumab significantly improves https://jcto.weill.cornell.edu/open_clinical_trials/phase-iii-trial-of-pembrolizumab-and-androgen-receptor-pathway-inhibitor-with-or-without-225ac-j591-for-progressive-metastatic-castration-resistant-prostate-cancer Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without... This is a clinical trial for adult men diagnosed with progressive metastatic castration-resistant prostate cancer. The main purpose of this study is to... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-pembrolizumab-with-radiotherapy-for-non-small-cell-lung-cancer-keynote-867 A trial looking at pembrolizumab with radiotherapy for non small cell lung cancer (KEYNOTE-867) This is a trial of pembrolizumab with stereotactic radiotherapy for early stage non small cell lung cancer. https://experts.umn.edu/en/publications/pembrolizumab-plus-olaparib-for-patients-with-previously-treated-/ Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected... for patients pembrolizumab plus olaparib https://adisinsight.springer.com/drugsafety/803871878?error=cookies_not_supported&code=1793f789-dfd0-4c7d-a19d-0ce1fe3205da Pembrolizumab/tepotinib - AdisInsight A 73-year-old woman exhibited lack of during treatment with pembrolizumab and developed grade 1 fatigue and grade 2 peripheral oedema during treatment with pembrolizumab adisinsight https://researchconnect.buffalo.edu/en/publications/pembrolizumab-versus-investigator-choice-chemotherapy-for-ipilimu/ Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma... pembrolizumab versus investigator choice chemotherapy https://digitalcommons.wustl.edu/oa_4/3440/ "Pembrolizumab for patients with non-Hodgkin lymphoma: Phase 1b KEYNOTE" by John Kuruvilla, Nancy L... The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who... https://adisinsight.springer.com/drugsafety/803929131?error=cookies_not_supported&code=dd3e5902-4ea0-4246-8a2e-a8ce35070d8d Pembrolizumab - AdisInsight A 64-year-old woman with stage VI non-small cell lung carcinoma receiving pembrolizumab experienced acute kidney injury with biopsy-proven pauci-immune pembrolizumab adisinsight https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/264/phase-ii-clinical-trial/?qd=29810228 A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and... New life-saving treatments for High risk, non-muscle invasive bladder cancer in clinical trial on A Phase II Clinical Trial to Study the Efficacy and Safety of... https://adisinsight.springer.com/drugsafety/803475452?error=cookies_not_supported&code=86c370dd-3e73-452f-9b2e-b3716498f86d Pembrolizumab - AdisInsight A 55-year-old man developed focal segmental glomerulosclerosis (FSGS) glomerular tip lesion (GTL) during treatment with pembrolizumab for bladder cancer.The pembrolizumab adisinsight https://pubmed.ncbi.nlm.nih.gov/38446675/?dopt=Abstract Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or... enfortumab vedotin pembrolizumab untreated advanced cancer https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-chemoradiotherapy-with-or-without-pembrolizumab-for-cervical-cancer-keynote-a18 A trial of chemoradiotherapy with or without pembrolizumab for cervical cancer (KEYNOTE-A18) This trial is looking at pembrolizumab for cervical cancer that has spread into the surrounding tissue (locally advanced) and has a high risk of coming back. https://adisinsight.springer.com/drugsafety/803928065?error=cookies_not_supported&code=9432bdd4-dc7e-4b5c-8b52-fdedc7d77cc8 Pembrolizumab - AdisInsight Three hundred and fifty-four patients [age and sex not stated] with early-stage triple-negative breast cancer in the UK received pembrolizumab in combination pembrolizumab adisinsight https://medicine.yale.edu/cancer/trial/a032201-testing-the-addition-of-the-anti-cancer-drug-tivozanib-to-immunotherapy-pembrolizumab-aft/ Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma -... This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with https://pmc.ncbi.nlm.nih.gov/articles/PMC11878863/ Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab - PMC A man in his 80s with metastatic melanoma presented with progressive dyspnea on exertion and dry cough after 7 cycles of pembrolizumab monotherapy. He was... unilateral following pembrolizumab pmc https://adisinsight.springer.com/drugsafety/803927096?error=cookies_not_supported&code=e8f373fa-3dc2-44aa-9c76-c615fc00c049 Pembrolizumab/Catequentinib - AdisInsight A report described 41 patients with advanced oral mucosal melanoma, whose ages and sexes were [not stated], who received pembrolizumab with anlotinib [doses, pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803926478?error=cookies_not_supported&code=da16c8dc-0a60-46dd-8b20-8f9cb8910ea2 Pembrolizumab - AdisInsight A 58-year-old man with KRAS-G12C-mutated stage IVB lung adenocarcinoma developed large-vessel vasculitis following treatment with pembrolizumab, carboplatin and pembrolizumab adisinsight https://researchportal.helsinki.fi/en/publications/real-world-outcome-of-neoadjuvant-therapy-with-or-without-pembrol/ Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast... https://adisinsight.springer.com/drugsafety/803868519?error=cookies_not_supported&code=d62b0c95-b08d-42cd-975d-7b87f56578dc Pembrolizumab - AdisInsight In a study of 47 patients conducted between between March 2022 and August 2023, a patient [age and sex not stated] was described, who exhibited lack of efficacy pembrolizumab adisinsight https://pubmed.ncbi.nlm.nih.gov/32979511/ Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy?... The EFS results from PURE-01 revealed that the immunotherapy effect was maintained post-RC in most patients. Pembrolizumab compared favorably with neoadjuvant... the administration https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT05633602&r=1 Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment... Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer... chemotherapy treatment non ramucirumab plus pembrolizumab https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-pembrolizumab-and-lenvatinib-for-head-and-neck-cancers-leap-010 A trial looking at pembrolizumab and lenvatinib for head and neck cancers (LEAP-010) This trial is looking at whether having lenvatinib with pembrolizumab works better than pembrolizumab on its own as a treatment for head and neck cancer. https://adisinsight.springer.com/drugsafety/803490466?error=cookies_not_supported&code=c1af44fc-fe57-4d57-bf50-65f6a3c66177 Atezolizumab/pembrolizumab - AdisInsight In a report 2 men were described, of which a 46-year-old man developed sensory neuropathy during treatment with pembrolizumab, and a 71-year-old man developed atezolizumab pembrolizumab adisinsight https://experts.arizona.edu/en/publications/combination-doxorubicin-and-pembrolizumab-in-patients-with-advanc/ Combination Doxorubicin and Pembrolizumab in Patients with Advanced Anthracycline-Naive Sarcoma -... in patients combination doxorubicin pembrolizumab https://scholars.lib.ntu.edu.tw/entities/publication/2d66ea1f-997f-49cf-a609-7c5f4470d379 Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for... https://www.nice.org.uk/guidance/ta939 Overview | Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or... Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical... overview pembrolizumab plus chemotherapy https://research.monash.edu/en/projects/phase-ii-study-of-pembrolizumab-checkpoint-blockade-following-che/ Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary... phase ii study pembrolizumab https://www.keytruda.com/qlex/ KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Learn about KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), an immunotherapy treatment. Talk to your doctor to find out more. keytruda pembrolizumab alfa https://tobias-lib.ub.uni-tuebingen.de/xmlui/handle/10900/151929 Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year Update of the Phase... https://pubmed.ncbi.nlm.nih.gov/41707170/ Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer Perioperative enfortumab vedotin plus pembrolizumab and surgery led to significantly better event-free and overall survival outcomes and a greater percentage... enfortumab vedotin perioperative pembrolizumab bladder cancer https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-pembrolizumab-and-usual-treatment-for-cervical-cancer-the-papaya-study A study of pembrolizumab and usual treatment for cervical cancer (The Papaya Study) This study looked at whether pembrolizumab could improve treatment for cancer of the cervix. a study https://adisinsight.springer.com/drugsafety/803693637?error=cookies_not_supported&code=4a56cdc0-4f64-4dbb-941a-176cec8c2c04 Osimertinib/pembrolizumab - AdisInsight A 66-year-old woman exhibited lack of efficacy during treatment with osimertinib and developed abdominal fibroinflammatory reaction during treatment with osimertinib pembrolizumab adisinsight https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-04436 Pembrolizumab Plus CA-4948 for the Treatment of Patients with Progressive Metastatic Urothelial... Pembrolizumab Plus CA-4948 for the Treatment of Patients with Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy https://repository.arizona.edu/handle/10150/657690?show=full Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line... https://adisinsight.springer.com/drugsafety/803591251?error=cookies_not_supported&code=84d56f78-a56c-40f9-8533-0ac446566ed6 Pembrolizumab - AdisInsight An 85-year-old woman developed bilateral corneal graft rejection during treatment with pembrolizumab for metastatic urothelial cell tumour.The woman visited the pembrolizumab adisinsight https://pubmed.ncbi.nlm.nih.gov/31050707/?dopt=Abstract Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine... ClinicalTrials.gov: NCT02256436. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-06279 Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects... Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT03553836&r=1 Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma... Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) https://adisinsight.springer.com/trials/700349736?error=cookies_not_supported&code=6058b3e6-2c04-4bb8-a5ef-0a90aeddd691 A retrospective, multicenter, cohort study of effectiveness and safety of pembrolizumab and... To investigate the effectiveness and safety of pembrolizumab and lenvatinib for recurrent endometrial cancer (EC) in a real-world setting. a retrospective cohort study multicenter effectiveness safety https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1445685/full Frontiers | Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a... Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet they can induce immune-related adverse events (irAEs), including cu... https://adisinsight.springer.com/drugsafety/803756008?error=cookies_not_supported&code=322a3a0b-7223-4380-b69d-7586057b99ec Pembrolizumab - AdisInsight A 96-year-old man developed myocarditis, myositis and hepatitis following treatment with pembrolizumab for melanoma.The man with stage III melanoma, prosthetic pembrolizumab adisinsight https://adisinsight.springer.com/drugsafety/803588762?error=cookies_not_supported&code=774921fe-83eb-4c83-b548-4f3bc8721bdc Enfortumab-vedotin/pembrolizumab - AdisInsight In a case series, three men aged 65-77 years were described, who developed cutaneous drug eruption and hypersensitivity reaction during treatment with enfortumab vedotin pembrolizumab adisinsight https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-08524&r=1 Pembrolizumab in Combination with Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients... Pembrolizumab in Combination with Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer?s=09 FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic... On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab... fda approves enfortumab vedotin https://www.news-medical.net/news/20240722/Combination-of-sEphB4-HSA-and-pembrolizumab-shows-promise-in-HPV-negative-EphrinB2-positive-HNSCC.aspx Combination of sEphB4-HSA and pembrolizumab shows promise in HPV-negative EphrinB2 positive HNSCC Jul 23, 2024 - A new research paper was published in Oncotarget's Volume 15 on July 10, 2024, entitled, "Improved efficacy of pembrolizumab combined with soluble... https://adisinsight.springer.com/drugsafety/803925395?error=cookies_not_supported&code=612abd81-f225-4a8c-9162-7bf0647991fe Pembrolizumab - AdisInsight A 64-year-old patient with metastatic squamous non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression developed immune pembrolizumab adisinsight https://medlineplus.gov/druginfo/meds/a625111.html Pembrolizumab and Berahyaluronidase alfa-pmph Injection: MedlinePlus Drug Information Pembrolizumab and Berahyaluronidase alfa-pmph Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus pembrolizumab alfa injection medlineplus drug https://pubmed.ncbi.nlm.nih.gov/27091806/ Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab by the monoclonal antibody pulmonary sarcoidosis induced https://www.mdpi.com/2072-6694/16/10/1825 Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1... The efficacy of immune checkpoint inhibitor (ICI) therapy concerning programmed death ligand 1 (PD-L1) status is well established in patients diagnosed with... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-v940-immunotherapy-with-pembrolizumab-for-people-with-high-risk-melanoma A study looking at V940 immunotherapy with pembrolizumab for people with high risk melanoma... This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma. https://adisinsight.springer.com/drugsafety/803517461?error=cookies_not_supported&code=dad49b62-8dc6-4877-9179-c5d96b030b8a Pembrolizumab/steroids - AdisInsight A 60-year-old man developed necrotizing myositis during treatment with pembrolizumab for grade IVA pulmonary squamous cell carcinoma. He also developed acute pembrolizumab steroids adisinsight https://adisinsight.springer.com/trials/700361326?error=cookies_not_supported&code=a7ad99f1-0e38-4c59-932f-9df5717d36e8 Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for... This phase III trial compares chemotherapy versus an immune checkpoint inhibitor drug called pembrolizumab plus chemotherapy in treating patients with classical phase iii randomized trial chemotherapy vs https://adisinsight.springer.com/trials/700194961?error=cookies_not_supported&code=4a002a78-24ae-4029-be6e-a654cef8a142 Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced... This phase Ib expansion study is investigating the tolerability, pharmacokinetics and preliminary efficacy of pembrolizumab (lambrolizumab) [MK 3475] in